Corval® Launches Corval 2.0 Commercialization Planning Platform for Early- to Mid-Stage Biopharma Companies
Corval®, the leader in cloud-based commercialization planning for early- to mid-stage biopharma companies, today announced the Corval 2.0 Platform, the second generation of its cloud-based software platform that enables company leaders to focus on the critical work of asset development and clinical trials by making commercialization planning quick, simple, and dynamic.
- Corval®, the leader in cloud-based commercialization planning for early- to mid-stage biopharma companies, today announced the Corval 2.0 Platform, the second generation of its cloud-based software platform that enables company leaders to focus on the critical work of asset development and clinical trials by making commercialization planning quick, simple, and dynamic.
- “The complex, fragmented, months-long commercialization planning process can challenge early- to mid-stage biopharma companies,” said Sue Nemetz, Founder and CEO of Corval LLC and The NemetzGroup LLC.
- With the Corval 2.0 Platform, even a team with no commercialization planning experience will have a step-by-step guide that sets their asset on a path to achieve maximum value.”
Informed by the voice of the customer and external commercialization experts, the Corval 2.0 Platform has been strategically and deliberately refined, upgraded, and enriched. - We designed the Corval Platform to simplify the process of commercialization planning and make it dynamic to reflect the reality and variabilities of asset development.”